Automated Multiple Ligand Screening by Frontal Affinity Chromatography-Mass Spectrometry (FAC-MS)

Transition Therapeutics Inc, Drug Discovery Group, Toronto, Ontario, Canada.
Journal of Biomolecular Screening (Impact Factor: 2.42). 04/2007; 12(2):167-74. DOI: 10.1177/1087057106297567
Source: PubMed


High-throughput screening (HTS) efforts to discover "hits" typically rely on the large-scale parallel screening of individual compounds with attempts to screen mixtures of compounds typically and, unfortunately, giving rise to false positives and false negatives due to the nature of the HTS readout (% inhibition/activation above a defined threshold) that makes deconvolution virtually intractable. Bioaffinity screening methods have emerged as an alternative or orthogonal method to classic HTS. One of these methods, frontal affinity chromatography coupled to mass spectrometry detection (FAC-MS), although still a relatively new technique, is turning out to be a viable screening tool. However, to push FAC-MS more to the forefront as a moderate primary HTS system (or a secondary screening assay), automation needs to be addressed. An automated FAC-MS system is described using 2 columns containing immobilized hERbeta, whereby while 1 column is being regenerated, the other is being used. The authors are extrapolating that in a continuous 24-h operation, the number of ligands screened could potentially approach 10,000. In addition, preliminary structure-activity relationship binding information (typically not seen in early primary HTS) can be obtained by observing the rank order of the library members in the various mixtures.

Download full-text


Available from: Andrew Pasternak, Jul 22, 2014
53 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: With more than 10 years of practical experience and theoretical analysis, fragment-based drug discovery (FBDD) has entered the mainstream of the pharmaceutical and biotech industries. An array of biophysical techniques has been used to detect the weak interaction between a fragment and the target. Each technique presents its own requirements regarding the fragment collection and the target; therefore, in order to optimize the potential of FBDD, the nature of the target should be a driving factor for simultaneous development of both the library and the screening technology. A roadmap is now available to guide fragment-to-lead evolution when structural information is available. The next challenge is to apply FBDD to targets for which high-resolution structural information is not available.
    Drug Discovery Today 01/2008; 12(23-24):1032-9. DOI:10.1016/j.drudis.2007.08.005 · 6.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel methodology is shown enabling the screening of mixtures of compounds for their affinity to a receptor protein. The system presented, dynamic protein-affinity chromatography solid-phase extraction (DPAC-SPE), overcomes the limitations of the existing methods by performing an incubation of the His-tagged protein with a mixture of possible ligands, which are still in their native conditions. This is followed by a fully automated affinity trapping step, coupled on-line to an LC-MS system in order to detect and identify the bound ligands. The system has been optimized using a commercially available on-line SPE system, using the estrogen receptor alpha (ERalpha) as model protein. A representative range of ligands with sub-nanomolar to millimolar affinities has been identified successfully from a mixture. The weakest binder that can be identified is norethindrone (approximately K(d)=0.1-1mM). The same setup also provides the possibilities to measure EC50 curves of both weak and strong binders.
    Journal of Chromatography A 10/2008; 1205(1-2):71-7. DOI:10.1016/j.chroma.2008.07.089 · 4.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A liquid chromatographic stationary phase containing immobilized membranes from cells expressing the P2Y-like receptor GPR17 is described. Cellular membranes from 1321N1 cells transiently transfected with GPR17 vector [GPR17+] and from the same cell line transfected with the corresponding empty vector [GPR17(-)] were entrapped on immobilized artificial membrane (IAM) support and packed into 6.6-mm-i.d. glass columns to create GPR17(+)-IAM and GPR17(-)-IAM stationary phases. Frontal chromatography experiments on both GPR17(+)-IAM and GPR17(-)-IAM demonstrated the presence of a specific interaction with GPR17 only in the former that was maximized by increasing the membrane/IAM ratio. GPR17(+)-IAM was used in frontal affinity chromatography experiments to calculate the dissociation constants (K(d)) of three ligands-the antagonist cangrelor (formerly AR-C69931MX, a P2Y(12)/P2Y(13) antagonist), MRS2179 (a P2Y(1) receptor antagonist), and the agonist UDP-all of which have been reported to also interact with GPR17. Immobilized GPR17 retained its ability to specifically bind the three analytes, as demonstrated by the agreement of the calculated K(d) values with previously reported data. Preliminary ranking experiments suggest the application of GPR17(+)-IAM in ranking affinity studies for the selection of new potential candidates.
    Analytical Biochemistry 10/2008; 384(1):123-9. DOI:10.1016/j.ab.2008.09.010 · 2.22 Impact Factor
Show more